Yarrow Bioscience, Inc. (YARW)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 350K 700K 1.1M FY21: 931K FY22: 477K FY23: 424K FY24: 501K FY25: 570K FY21 FY22 FY23 FY24 FY25

Gross Profit Annual

-7M 0 7M 14M 21M FY18: 3.6M FY19: 443K FY20: 19.6M FY21: -2.4M FY18 FY19 FY20 FY21

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Annual

-45M -30M -15M 0 15M 30M 45M FY21: -38.9M FY22: -34.3M FY23: -29.3M FY24: -43.6M FY25: -29.7M FY21 FY22 FY23 FY24 FY25

Net Income Annual

-75M -50M -25M 0 25M 50M 75M FY21: -73.3M FY22: -23.2M FY23: -28.5M FY24: -39.8M FY25: -26.5M FY21 FY22 FY23 FY24 FY25

Cost of Revenue Annual

0 1.5M 3M 4.5M FY18: 0 FY19: 0 FY20: 1.4M FY21: 3.3M FY18 FY19 FY20 FY21

Operating Cash Flow Annual

-60M -40M -20M 0 20M 40M 60M FY21: -56.4M FY22: -29.2M FY23: -25.3M FY24: -34M FY25: -33.1M FY21 FY22 FY23 FY24 FY25

Free Cash Flow Annual

-150M -100M -50M 0 50M 100M 150M FY20: -137.2M FY21: -56.4M FY23: -25.3M FY24: -34.1M FY25: -33.1M FY20 FY21 FY23 FY24 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 15M 30M 45M FY21: 2.9M FY22: 3.2M FY23: 10.3M FY24: 42.6M FY25: 42.8M FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-30.00 -20.00 -10.00 0.00 10.00 20.00 30.00 Q3 '20: 2.54 Q4 '20: -1.08 Q1 '21: -5.29 Q2 '21: -0.85 Q3 '21: -0.67 Q4 '21: -25.64 Q1 '22: -23.71 Q2 '22: -25.95 Q3 '22: -28.48 Q4 '22: -7.16 Q1 '23: -10.41 Q2 '23: -10.87 Q3 '23: -9.94 Q4 '23: -2.78 Q1 '24: -1.19 Q2 '24: 1.68 Q3 '24: 3.40 Q4 '24: -0.94 Q1 '25: -0.99 Q2 '25: -7.50 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.